ImmunoGen Announces New License Agreement with Novartis

By: Benzinga
ImmunoGen (NASDAQ: IMGN ) today announced that Novartis (NYSE: NVS ) has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.